Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01888198 · ClinicalTrials.gov registry record
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
A clinical trial of Renal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 294
- Enrollment target
- 6
- Study locations
NCT01888198: Active study of Renal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01888198 is a study of Renal Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 294 participants, below the 600-participant average among 29 other Renal Cancer trials with a reported enrollment target (51% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01888198, a study of Renal Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 294 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection
Primary Outcome
To assess renal ablation outcomes using standard quality of life measures. Specifically, quality of life outcomes measures will be analyzed with respect to ablation procedure characteristics including ablation technique and anesthesia type as well as renal mass characteristics such as size, location and pathologic tumor type.
Conditions Studied
Interventions
- BEHAVIORAL (EORTC QLQ-C30) questionnaire
- BEHAVIORAL EuroQol EQ-5D 7-item questionnaire
Study Locations (6)
California
- University of California, Los Angeles - Los Angeles
Maryland
- University of Maryland Medical Center - Baltimore
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Rhode Island
- Rhode Island Hospital - Providence
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
What the registry record for NCT01888198 still lists
NCT01888198 is an observational study that tracks outcomes without assigning an intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, below the 600-participant average among 29 other Renal Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions - of which (EORTC QLQ-C30) questionnaire is the first listed.
NCT01888198 lists 6 locations in 6 states (California, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT01888198 about?
NCT01888198 is a clinical study titled "Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment". The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or...
What is the current status of trial NCT01888198?
This trial is currently active not recruiting. The enrollment target is 294 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT01888198 study?
This clinical trial studies the following conditions: Renal Cancer.
What interventions are being tested in trial NCT01888198?
The interventions under investigation include: (EORTC QLQ-C30) questionnaire (BEHAVIORAL), EuroQol EQ-5D 7-item questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT01888198?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01888198 being conducted?
This trial has 6 study locations across California, Maryland, New York, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01888198's enrollment target sits among peer trials
294 9th of 29 higher than 21 of 29 other Renal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Kidney Cancer DNA Registry
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RECRUITING · Phase 1
-
Advanced Diffusion Imaging in Renal Cancer Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia